The Zhitong Finance App learned that recently, Changfeng Pharmaceutical (02652.HK) announced that its first-in-class (first-in-class) phase I clinical trial of ICF004 (chemical drug class 1) for the treatment of interstitial lung disease (ILD) has successfully completed the enrollment and administration of the first healthy volunteer. The project is a scientific research result developed by Changfeng Pharmaceutical in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. The drug candidate has officially entered a new stage of clinical trial in humans.
Zhitongcaijing · 3d ago
Share
Listen to the news
The Zhitong Finance App learned that recently, Changfeng Pharmaceutical (02652.HK) announced that its first-in-class (first-in-class) phase I clinical trial of ICF004 (chemical drug class 1) for the treatment of interstitial lung disease (ILD) has successfully completed the enrollment and administration of the first healthy volunteer. The project is a scientific research result developed by Changfeng Pharmaceutical in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. The drug candidate has officially entered a new stage of clinical trial in humans.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending